

Gemcitabine (1250mg/m²) Monotherapy - 21 dayⁱ

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Status
Loco-regionally recurrent/metastatic nasopharyngeal cancer not amenable for local curative therapy.	C11	00514a	Hospital

**If the reimbursement status is not defined,ⁱⁱ the indication has yet to be assessed through the formal HSE reimbursement process.*

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Facilities to treat anaphylaxis MUST be present when Gemcitabine is administered.

Gemcitabine is administered once weekly for 2 consecutive weeks followed by a 1 week pause (1 cycle = 21 days) for a maximum of 6 cycles or until disease progression or unacceptable toxicity develops.

Day	Drug	Dose	Route	Diluent & Rate	Cycle
1 and 8	Gemcitabine	1250mg/m ²	IV infusion	250ml NaCl 0.9% over 30mins	Every 21 days

ELIGIBILITY:

- Indications as above
- ECOG 0-2

EXCLUSIONS:

- Hypersensitivity to gemcitabine or any of the excipients
- Breast feeding

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist

TESTS:

Baseline tests:

- FBC, renal and liver profile

Regular tests:

- FBC prior to each treatment
- Renal and liver profile prior to each cycle

NCCP Regimen: Gemcitabine (1250mg/m ²) Monotherapy - 21 day	Published: 07/11/2018 Review: 07/11/2020	Version number: 1
Tumour Group: Head and Neck NCCP Regimen Code: 00514	ISMO Contributor: Prof Maccon Keane	Page 1 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.

Haematological:

Prior to commencing a new treatment cycle (i.e. day 1), ANC must be $\geq 1.0 \times 10^9/L$ and platelets $\geq 100 \times 10^9/L$.

Table 1: Dose modifications for gemcitabine within a cycle (i.e day 8)

ANC ($\times 10^9 /L$)		Platelet count ($\times 10^9 /L$)		Other toxicity	Recommended dose of Gemcitabine
≥ 1	and	≥ 100			100 %
0.5- 1	or	50-100			75%
< 0.5	or	<50			Omit. Do not restart treatment until ANC ≥ 0.5 and platelets ≥ 50
ANC < 0.5 for ≥ 5 days or ANC < 0.1 for ≥ 3 days or Any incidence of febrile neutropenia	or	< 25	or	cycle delay of >1 week due to any toxicity	Reduce dose to 75% of the original cycle initiation dose for all subsequent cycles.

Renal and Hepatic Impairment:

Table 2: Dose modification of Gemcitabine in renal and hepatic impairment

Drug	Renal Impairment		Hepatic Impairment
Gemcitabine	Cr Cl (ml/min)	Dose	AST elevations do not seem to cause dose limiting toxicities. If bilirubin > 27 micromol/L, initiate treatment with dose of 800 mg/m ² .
	≥ 30	100%	
	<30	Consider dose reduction clinical decision	

Management of adverse events:

Table 3a: Dose Modification of gemcitabine for Adverse Events

Adverse reactions	Recommended dose modification
Grade ≥ 2 Pneumonitis	Discontinue gemcitabine
Grade > 3 Non-haematological toxicity (except nausea/vomiting)	Therapy with gemcitabine should be withheld (until toxicity has resolved to grade ≤ 1) and may be resumed with 50% dose reduction or treatment discontinued at discretion of prescribing consultant.
Grade > 4 Non-haematological toxicity	Discontinue treatment

NCCP Regimen: Gemcitabine (1250mg/m ²) Monotherapy - 21 day	Published: 07/11/2018 Review: 07/11/2020	Version number: 1
Tumour Group: Head and Neck NCCP Regimen Code: 00514	ISMO Contributor: Prof Maccon Keane	Page 2 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Gemcitabine- Low (**Refer to local policy**).

PREMEDICATIONS: None usually required

OTHER SUPPORTIVE CARE: No specific recommendations

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Pulmonary Toxicity:** Acute shortness of breath may occur. Discontinue treatment if drug-induced pneumonitis is suspected.
- **Cardiovascular:** Due to the risk of cardiac and/or vascular disorders with Gemcitabine, particular caution must be exercised with patients presenting a history of cardiovascular events.
- **Irreversible renal failure:** In association with haemolytic uraemic syndrome may occur rarely with gemcitabine. Use caution with pre-existing renal impairment.

DRUG INTERACTIONS:

- Current drug interaction databases should be consulted for more information.

ATC CODE:

Gemcitabine L01BC05

REFERENCES:

1. Foo, KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. *Ann Oncol* 2002;13:150-156.
2. EVIQ Protocol Summary for Nasopharyngeal recurrent or metastatic Gemcitabine- Using Protocol code 1510 revised October 2016.
3. BCCA Protocol Summary for Treatment of Loco-regionally Recurrent/Metastatic Nasopharyngeal Cancer not Amenable for Local Curative Therapy with Gemcitabine. Using Gemcitabine Protocol code HNAVGEM revised November 2012
4. Gemcitabine 40 mg/ml Concentrate for Solution for Infusion Summary of Product Characteristics Accessed Sept 18. Available at http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1380-015-003_16042013100051.pdf
5. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf>

NCCP Regimen: Gemcitabine (1250mg/m ²) Monotherapy - 21 day	Published: 07/11/2018 Review: 07/11/2020	Version number: 1
Tumour Group: Head and Neck NCCP Regimen Code: 00514	ISMO Contributor: Prof Maccon Keane	Page 3 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

6. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-cytotoxics.pdf>

Version	Date	Amendment	Approved By
1	07/11/2018		Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ This indication is outside the licensed indications for Gemcitabine in Ireland. Patients should be informed of the unlicensed nature of this indication and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be aware of their responsibility in communicating any relevant information to the patient and also in ensuring that the unlicensed or "off label" indication has been acknowledged by the hospital's Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

ⁱⁱ ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;
<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

NCCP Regimen: Gemcitabine (1250mg/m ²) Monotherapy - 21 day	Published: 07/11/2018 Review: 07/11/2020	Version number: 1
Tumour Group: Head and Neck NCCP Regimen Code: 00514	ISMO Contributor: Prof Maccon Keane	Page 4 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		